CD30 (Reed-Sternberg Cell Marker) Ab-1 (Clone Ber-H2)

Mouse Monoclonal Antibody
Cat. #MS-361-S0, -S1, or -S (0.1ml, 0.5ml, or 1.0ml Supernatant)
Cat. #MS-361-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining)
Cat. #MS-361-PCS (5 Slides) (Positive Control for Histology)

Description: CD30, a single chain glycoprotein, is synthesized as a 90kDa precursor which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. The CD30/Ki-1 antigen is expressed by mononuclear Hodgkin and multinucleated Reed-Sternberg cells in Hodgkin’s disease, by the tumor cells of a majority of anaplastic large cell lymphomas, and by a varying proportion of activated T and B cells.

Comments: Ab-1 distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).

Mol. Wt. of Antigen: 120kDa (mature), 95kDa (precursor)
Epitope: Not determined
Clone Designation: Ber-H2
Ig Isotype / Light Chain: IgG1 / κ

Immunogen: Co cells.

Applications and Suggested Dilutions:
- Immunohistology (Formalin/paraffin)
  (Ab 1:40-1:80 for 20 min at RT using UltraVision LP detection systems)

  (Ab 1:40 for 20 min at RT using UltraVision Quanto detection systems)

  [Staining of formalin-fixed tissues REQUIRES boiling tissue sections in 1mM EDTA, pH 8.0, (NEOMARKERS’ Cat. #AP-9004), for 10-20 min followed by cooling at RT for 20 min.]

The optimal dilution for a specific application should be determined by the investigator.

Positive Control: Hodgkin’s lymphoma

For Research Use Only
CD30 (Reed-Sternberg Cell Marker) Ab-1 (Clone Ber-H2)
Mouse Monoclonal Antibody
Cat. #MS-361-S0, -S1, or -S (0.1ml, 0.5ml, or 1.0ml Supernatant)
Cat. #MS-361-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining)
Cat. #MS-361-PCS (5 Slides) (Positive Control for Histology)

Additional Key Reference:
4. Terenzi A; Bolognesi A; Pasqualucci L; Fleglhi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; et al. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. British Journal of Haematology, 1996 Mar, 92(4):872-9.
7. Fraga M; Brousset P; Schlaifer D; Payen C; Robert A; Rubie H; Huguet-Rigal F; Delsol G. Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. American Journal of Clinical Pathology, 1995 Jan, 103(1):82-9.
8. Horn-Lohrens O; Tiemann M; Lange H; Kobarg J; Hafner M; Hansen H; Sterry W; Parwaresch RM; Lemke H. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). International Journal of Cancer, 1995 Feb 8, 60(4):539-44.
20. Cambiaggi A; Cantoni C; Marciano S; De Totero D; Pileri S; Tazzari PL; Stein H; Ferrini S. Cultured human NK cells express the Ki-1/CD30 antigen. British Journal of Haematology, 1993 Oct, 85(2):270-6.

Please note this data sheet has been changed effective March 29, 2010

Thermo Fisher Scientific
Anatomical Pathology
46360 Fremont Blvd.
Fremont, CA 94538, USA
Tel: 1-510-771-1560
Fax: 1-510-771-1570
http://www.thermo.com/labvision

Lab Vision Corporation
Registered in the United States Patent & Trademark Office
NEOMARKERS® is a registered trademark of Thermo Fisher Scientific

Lab Vision UK Limited
93-96 Chadwick Road, Astmoor
Runcorn, Cheshire WA7 1PR, UK
Tel: 44-1928-562600
Fax: 44-1928-562627
Labvision.uk@thermofisher.com

Clinical customers please refer to IVD / ASR Data Sheet
CD30 (Reed-Sternberg Cell Marker) Ab-1 (Clone Ber-H2)

Mouse Monoclonal Antibody

Cat. #MS-361-S0, -S1, or -S (0.1ml, 0.5ml, or 1.0ml Supernatant)
Cat. #MS-361-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining)
Cat. #MS-361-PCS (5 Slides) (Positive Control for Histology)

Please note this data sheet has been changed effective March 29, 2010


25. Parente A; De Luca P; Bolognesi A; Barbieri L; Battelli MG; Abbondanza A; Sande MJ; Gigliano GS; Tazzari PL; Stirpe F. Purification and partial characterization of single-chain ribosome-inactivating proteins from the seeds of Phytolacca dioica L. Biochim Biophys Acta, 1993 Oct 1, 1216(1):43-9.


27. Vanbockrijck M; Cabooter M; Casselman J; Vanvuchelen and Laboratory Medicine, 1992 Nov, 116(11):1192-6.

28. Durkop H; Latza U; Hummel M; Eitelbach F; Seed B; Soria RM; Vanbockrijck M; Cabooter M; Casselman J; Vanvuchelen and Laboratory Medicine, 1992 Nov, 116(11):1192-6.

29. Falini B; Bolognesi A; Flenghi L; Tazzari PL; Broc MK; Stein H; Durkop H; Aversa F; Corneli P; Pizzolo G; et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet, 1992 May 16, 339(8803):1195-6.


31. Kanzaki T; Kubonishi I; Eguchi T; Yano S; Sonobe H; Ohyashiki JH; Ohyashiki K; Toyama K; Ohshutsi Y; Miyoshi I. Establishment of a new Hodgkin's cell line (HD-70) of B-cell origin. Cancer, 1992 Feb 15, 69(4):1034-41.


38. Carbone A; Gloghini A; De Re V; Tamaro P; Boiocchi M; Volpe R. Histopathologic, immunophenotypic, and genotypic analysis of Ki-1 anaplastic large cell lymphomas that express histioocyte-associated antigens. Cancer, 1990 Dec 15, 66(12):2547-56.


42. Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfrendenschuh M; Diehl V; Thorpe P. Evaluation of ricin A chain-containing immunotoxins directed against the CD30

43. Engert A; Martin G; Pfleundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. Cancer Research, 1990 May 15, 50(10):2929-35.

44. Falini B; Pileri S; Stein H; Dienesman D; Dallenbach F; Delsol G; Minelli O; Poggi S; Martelli MF; Pallesen G; et al. Variable expression of leukocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: implications for the differential diagnosis between lymphoid and nonlymphoid malignancies. Human Pathology, 1990 Jun, 21(6):624-9.


46. Kinney MC; Glick AD; Stein H; Collins RD. Comparison of anaplastic large cell Ki-1 lymphomas and micrivilous lymphomas in their immunologic and ultrastructural features. American Journal of Surgical Pathology, 1990 Nov, 14(11):1047-60.


50. Beljaards RC; Meijer CJ; Scheffcr E; Toonstra J; van Vloten WA; van der Putte SC; Geerts ML; Willemsen R. Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients. American Journal of Pathology, 1989 Dec, 135(6):1169-78.


54. Hansmann ML; Stein H; Fellbaum C; Hui PK; Parwearsch MR; Lennert K. Nodal paragranuloma can transform into high-grade malignant lymphoma of B type. Human Pathology, 1989 Dec, 20(12):1169-75.


63. Teerenhovi L; Lindholm C; Pakkala A; Franssila K; Stein H; Knuitila S. Unique display of a pathologic karyotype in Hodgkin's disease by Reed-Sternberg cells. and Cytogenetics, 1988 Sep, 34(2):215-21.


65. Ralfkiaer E; Bosq J; Gatter KC; Schwarting R; Gerdes J; Stein H; Mason DY. Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid
CD30 (Reed-Sternberg Cell Marker) Ab-1 (Clone Ber-H2)

Mouse Monoclonal Antibody
Cat. #MS-361-S0, -S1, or -S (0.1ml, 0.5ml, or 1.0ml Supernatant)
Cat. #MS-361-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining)
Cat. #MS-361-PCS (5 Slides) (Positive Control for Histology)

Please note this data sheet has been changed effective March 29, 2010